A variety of studies have shown that some activated nuclear receptors (NRs), especially the glucorticoid receptor, the estrogen receptor and peroxisome proliferator-activated receptor, can inhibit the activity of the transcription factor nuclear factor jB (NF-jB), which plays a key role in the control of genes involved in inflammation, cell proliferation and apoptosis. This review describes the molecular mechanisms of cross-talk between NRs and NF-jB and the biological relevance of this crosstalk. The importance and mechanistic aspects of selective NR modulation are discussed. Also included are future research prospects, which will lead to a new era in the field of NR research with the aim of specifically inhibiting NF-jB-driven gene expression for anti-inflammatory, anti-tumor and immune-modulatory purposes.
Introduction
Approximately 60 years ago, the observation that an attack of jaundice led to excellent remission in a patient with severe rheumatoid arthritis sparked the belief that the early pathology of this inflammatory disease was reversible. As remissions of rheumatoid arthritis had also been observed during pregnancy, Philip Hench initiated attempts to identify the 'anti-rheumatic substance X', as well as the female sex hormone, which might be responsible for these remissions (Glyn, 1998) .
Based on the knowledge that we have today, these phenomena no doubt exemplify the negative cross-talk of glucocorticoid and sex steroid hormones with nuclear factor kB (NF-kB), a dimeric transcription factor (TF) recognized as a key regulator of pro-inflammatory gene expression (see Gilmore, 2006; Hoffmann et al., 2006) . Corticosteroids, or steroidal hormones, were initially only used as a replacement therapy in adrenocortical deficiency states. Cortisone, or at that time called Compound E, had been isolated and identified by Kendall and Reichstein as early as 1935 (Glyn, 1998) . As jaundice leads to retention of bile acids in the body and because of a structural relationship between bile acids and 'cortin substances' (isolated from the adrenal cortex), the combined efforts of several groups eventually led to the exciting discovery that cortisone was possibly the miracle drug that could relieve the debilitating symptoms of chronic rheumatoid arthritis.
However, the spectacular effects of cortisone on rheumathoid arthritis appeared to be only temporary and reversible. Moreover, the finding that long-term corticosteroid treatment of chronic ailments is accompanied by the appearance of a range of negative side effects further overshadowed the initial successes of cortisone. Among these, side effects are increased blood sugar levels leading to diabetes, cataracts, excessive weight gain, redistributed fat (leading to puffy cheeks, swelling of the abdomen and a hunchback), osteoporosis, muscle wasting, psychosis and neurosis. The reason for the occurrence of multiple side effects is not surprising now that we understand many of the physiological roles of these hormones in the body. Glucocorticoids, the secretion of which is subject to a strict hypothalamus-pituitary-adrenal-axis feedback control, exert a variety of biological actions, including the regulation of glucose and lipid metabolism, blood pressure, electrolyte balance, and modulation of the immune, cardiovascular and central nervous systems (Reichardt et al., 2000; Sapolsky et al., 2000; de Kloet et al., 2005) . Long-term and/or high-dose administration of synthetic glucocorticoids or corticosteroids is therefore certain to have unwanted effects on a variety of physiological processes in the organism.
Despite continuous efforts of the pharmaceutical industry to design anti-inflammatory compounds that can circumvent side effects while maintaining effectiveness, no other drug has approached cortisone's therapeutic benefits. Thus, corticosteroids remain the mainstay for the treatment of asthma (Barnes, 2006) , and are also used in combination with other therapeutics to treat a wide range of chronic autoimmune and inflammatory diseases, including rheumatoid arthritis, atopy, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel disease, etc. Similarly, due to their potent immunosuppressive effects, glucocorticoids are used to prevent organ rejection after transplantation and, because of their immune cell apoptosis-inducing abilities, they are also used in the treatment of certain types of B-and T-cell lymphoma (Jehn and Osborne, 1997) . Because glucocorticoids efficiently block leukocyte migration towards sites of inflammation (Cato and Wade, 1996) , by inhibiting relevant NF-kB-driven cytokines and chemokines, the general symptoms of inflammation are quickly dampened.
Since the discovery of NF-kB, major advances have been made in understanding the molecular mechanisms underlying normal and pathologic inflammatory responses, and recent progress has also led to a more detailed understanding of fundamental mechanisms of gene transcription. For example, much attention now focuses on learning how to read and interpret the 'histone code', inferring an additional level of dynamic gene regulation. Chromatin organization plays a major role in controlling the dynamic nature of NF-kB recruitment to target genes and represents an integration point for mediating diverse interactions between TFs (Burkhart et al., 2005; Natoli et al., 2005; Natoli and De Santa, 2006; Vanden Berghe et al., 2006b ). This information is paramount for researchers interested in mechanisms of hormonal repression of NF-kB-driven gene expression, as additional key regulators of this process are still emerging. Novel insights into hormonal repression of NF-kB may provide a solution for patients who have become resistant to classical hormone-based therapies. This review describes the cross-talk between nuclear receptors (NRs), many of them are receptors for steroid hormones, and NF-kB, and the biological and therapeutic relevance of this cross-talk.
Signaling by hormone receptors
Due to their lipophilic nature, steroid hormones (e.g., glucocorticoids, estrogens, progesterone, mineralocorticoids, androgens, vitamin D 3 , ecdysone, oxysterols and bile acids), retinoic acids, fatty acids and prostaglandins diffuse freely across the plasma membrane without the need for a membrane receptor. Once inside the cell, these compounds exert most of their effects by binding to specific intracellular receptors, termed NRs, which belong to a superfamily of ligand-inducible TFs. Ligand-activated NRs, mostly as homo-or heterodimers, can directly regulate their individual gene programs by contacting promoters/enhancers at sequence-specific DNA response elements; however, these NR-ligand complexes can also influence other signaling pathways (Resche-Rigon and Gronemeyer, 1998) , such as those driven by NF-kB, cAMP-responsive-element binding protein (CREB), activator protein (AP-1) or signal transducers and activators of transcription (STATs).
Nuclear receptors share a common structural organization: an N-terminal variable domain or A/B domain, with at least one constitutive transactivation subdomain (AF-1) and several transactivation subdomains; a central DNA-binding domain (DBD or C domain), involved in dimerization and contacting DNA (through 8 cysteine residues that form two zinc ion-containing tetrahedric structures); a less conserved D region containing a nuclear localization signal, sometimes overlapping with the C domain; and a C-terminal ligand-binding domain (LBD or E domain) , which is moderately conserved at the level of DNA sequence but has a well conserved secondary alpha-helical structure. Included in the E domain is the AF-2 transactivation subdomain, a strong dimerization interface, a second nuclear localization signal and often a transrepression function.
Surprisingly, 48 genes in man (as compared to more than 270 genes in Drosophila) are enough to code for the phylogenetically related, abundant transcriptional regulator class of NRs. In man, the glucocorticoid receptor (GR) and the mineralocorticoid receptor (MR) are most closely related, and are grouped together with the progesterone receptor (PR), the androgen receptor (AR) and the estrogen receptor (ER) (Robinson-Rechavi et al., 2003) . Together with the peroxisome proliferator-activated receptor a (PPARa) receptor (belonging to a different group), these NRs have been shown to interact and interfere with the transcriptional activity of NF-kB, representing an important regulatory link between the endocrine and immune systems.
Regulation of transcription by NRs can be effected by three main mechanisms: ligand-independent gene repression, ligand-dependent transactivation and liganddependent transrepression . In the classical model of steroid hormone receptor function, unliganded receptors such as GR, MR, PR and ER are kept in the cytoplasm by chaperone proteins (such as Hsp70, Hsp90 and immunophilins) (Pratt and Toft, 1997) and only travel into the nucleus after a ligandinduced conformational change, which exposes a nuclear localization signal (Figure 1 ). However, recent data indicate that, in fact, a continuous dynamic NR shuttling between the nuclear and cytoplasmic compartments takes place, and, as hypothesized for ER, this may allow the receptor to exert both genomic (nuclear) and non-genomic (cytoplasmic) activities (Lo¨sel and Wehling, 2003; Leclercq et al., 2006) . For GR too, the subcellular localization of both liganded and unliganded receptors is at any given time the net result of a dynamic equilibrium determined by the rates of nuclear import and export (Savory et al., 1999) , although the import/ export mechanisms are not precisely known (Liu and DeFranco, 1999) .
Other NRs, such as RAR/RXR and PPAR constitutively reside in the nucleus, bound to DNA in the unliganded state, and are kept inactive through interaction with a nuclear corepressor complex, consisting of nuclear corepressor (NcoR) or SMRT (silencing mediator of retinoic-acid and thyroid hormone receptors) and histone deacetylases (HDACs), which possess histone deacetylase activity. Indeed, it is generally assumed that chromatin condensation and gene repression are linked to the activity of histone deacetylases, whereas chromatin relaxation and the promotion of gene expression involve the activity of histone acetyltransferases (HATs) (Davie and Spencer, 1999) . With the unliganded DNA-bound NRs, ligand binding induces a conformational change in the AF-2 domain, which is the a-helical region in the receptor LBD. This conformational change promotes dissociation of the repressor complex (a process called 'derepression'), which involves ubiquitination and proteasomal degradation of NcoR , followed by substitution of the corepressor by a coactivator complex, harboring HAT activity. This hormone-dependent corepressor/coactivator switch is also known as the 'cofactor exchange' model (Torchia et al., 1998; Glass and Rosenfeld, 2000) . Coactivator molecules, such as CBP, p300 or SRC-1 (steroid receptor coactivator-1) mediate the transcriptional activity of many TFs, including the NRs, by means of their HAT functions, Figure 1 Scheme depicting activation pathways and nuclear cross-talk between NF-kB and GR. TNF, a pro-inflammatory cytokine, binds to the membrane-bound TNF-receptor, which initiates recruitment of various adaptor proteins and activation of a complex cytoplasmic kinase cascade. Representative and important proteins that make up the TNF-R-associated protein complex and IKK complex are depicted in the red and green dotted circles, respectively. Activation of the IKK complex leads to phosphorylation and ubiquitination of IkBa, the cytoplasmic inhibitor of NF-kB. Subsequent degradation of IkBa by the proteasome releases NF-kB (p50/RelA heterodimer) and allows its translocation to the nucleus. RelA is phosphorylated by cytoplasmic kinases but also additionally by the nuclear kinase MSK-1 (Vermeulen et al., 2003) . NF-kB is the exclusive transcription factor for induction of the IL-6 gene in response to TNF and is the final switch that activates a largely pre-existing 'enhanceosome' multiprotein complex at the level of the IL-6 promoter. The enhanceosome also displays phosphorylation (i.e., MSK-and/or IKKa-dependent) and acetylation (i.e., CBP/HAT-dependent) activity, facilitating IL-6 gene expression (Vanden Berghe et al., 1999a; Vermeulen et al., 2003; Yamamoto and Gaynor, 2004) . GR is a transcription factor that predominantly resides in the cytoplasm in an inactive state. Ligand binding induces a conformational change in GR, allowing the release of its cytoplasmic chaperones and enabling GR's nuclear translocation. At the IL-6 enhanceosome, the activated GR interferes with the transcriptional activity of NF-kB through distinct, but non-exclusive mechanisms. Three such mechanisms are illustrated: direct physical interaction between RelA and GR De Bosscher et al., 1997) , recruitment of corepressor molecules (HDAC2) (Ito et al., 2000) , and blocking of a critical phosphorylation on RNA polymerase II (Nissen and Yamamoto, 2000) . GR has also been found to interact with NF-kB family members in the cytoplasm (represented by the complex in the gray dotted line). The biological relevance of this cytoplasmic interaction remains to be established, but may reflect a dynamic nucleocytoplasmic shuttling process, acting as a biological sensor. Note that this figure represents a simplified static model of the IL-6 enhanceosome. It is clear that other factors may be present and that not all factors shown may be present on the promoter simultaneously.
ultimately leading to a more relaxed chromatin structure and, as such, promoting gene activation.
A wide range of NR-interacting cofactor molecules, which are predominantly nuclear proteins that form a bridge between TFs and the basal transcription machinery (BTM), have been identified, including the p160 family members (e.g., SRC-1, TIF2/GRIP), PPARg coactivator-1 (PGC-1), NcoR, SMRT, transducin-blike 1, etc. (for extensive reviews, see McKenna and O'Malley, 2002; Perissi et al., 2004; Perissi and Rosenfeld, 2005; Spiegelman and Heinrich, 2004) . Coactivator molecules interact with liganded NRs via conserved LXXLL (X, any amino acid) motifs, which make initial contacts with several helices (notably helix 12/AF2) in the LBD of the NR (McKenna and O'Malley, 2002) . Subsequently, the HAT-containing complex dissociates and a second coactivator complex TRIP/DRIP/ARC is assembled to contact the basal transcriptional machinery, finally resulting in target gene activation. Upon ERa activation, cyclic and dynamic recruitment of a plethora of protein complexes, including chromatin-remodeling factors, histone (de)acetyl-and methyl-transferases, the mediator complex (involved in direct recruitment of the general TF and RNA polymerase II to the promoter), proteasomal subunits, heat shock proteins (Hsp's), general TFs and RNA polymerase II, has been demonstrated at ER-targeted promoters (Glass and Rosenfeld, 2000; Malik and Roeder, 2000; Lewis and Reinberg, 2003; Me´tivier et al., 2003 Me´tivier et al., , 2006 . Although the functionality of HAT (chromatin-relaxing and thus gene-activating) and HDAC (chromatin-condensing and thus generepressing) complexes in gene transcription is well established and generally accepted, it remains puzzling how chromatin relaxation is initiated. As chromatin severely restricts TF access to promoters and determines TF-binding kinetics, one can question whether TF recruitment of HATs is the driving force for chromatin relaxation, as binding of the TF-cofactor complex is determined by a 'pre-relaxed' chromatin condition (also considered as the chicken and egg problem) (Natoli et al., 2005) . Of special interest, hormone receptordependent large-scale chromatin decondensation has been observed, which does not require transcriptional activation, ligand-induced coactivator interactions or histone hyperacetylation (Nye et al., 2002) . Alternative to the cyclic cofactor recruitment model for ER, occupancy of the AR coactivator complex on PSA gene-regulatory regions was found to increase only gradually, with a peak at 16 h after the binding of androgen to the AR, and better fits a model of integrated DNA looping and pol II tracking, compatible with long-range interactions between enhancer and promoter regions (Chakalova et al., 2005; Wang et al., 2005; West and Fraser, 2005) . Overall, hormone signaling requires an intimate and dynamic interplay of enzyme cofactor complexes with their chromatin environment. Below, it is discussed in detail how crosstalk of hormone signaling with the inflammatory stress factor NF-kB can specifically modulate target gene expression.
Cross-talk between NRs and NF-jB
Cross-talk is defined as the interaction between different TFs, resulting in either a cooperative enhancement or inhibition of gene expression, with an important consequence of cross-talk being that the number of possible gene-specific responses is greatly increased in a cell type-dependent manner. In addition to the direct effects of NRs on target genes by binding to hormone response DNA elements, an important second mechanism of action of activated NRs, including GR, ER, PR and PPAR, is their interference with other signaling pathways (e.g., inhibition of gene activation by NF-kB or AP-1). This NR-TF cross-talk is thought to occur primarily in the nucleus, although cytosolic mechanisms have also been reported.
NF-kB is the collective name given to a family of ubiquitous TFs, activated in response to inflammatory stimuli and environmental stressors, and the activation of NF-kB is required for the increased expression of many crucial inflammatory and immune response genes (see Pahl, 1999; Gilmore, 2006; www.nf-kb.org) . The NF-kB TFs are related to one another through a conserved N-terminal DNA-binding/dimerization domain, called the Rel homology domain (Gilmore, 2006) . The prototypical NF-kB heterodimer consists of RelA (p65) and p50, but NF-kB complexes can also include homodimers and heterodimers of the p52, c-Rel and RelB subunits. In most cells, NF-kB complexes are in an inactive, cytoplasmic state by virtue of being bound to an inhibitor kB (IkB) inhibitor protein. Upon stimulation of the cell with an appropriate signal, NF-kB is activated by inactivation of IkB, which occurs via IkB kinase (IKK)-mediated phosphorylation and proteasome-mediated degradation of IkB. This then allows the nuclear translocation and accumulation of NF-kB, leading to gene induction once NF-kB binds to target gene DNA (see Hayden and Ghosh, 2004; Gilmore, 2006; Scheidereit, 2006) (Figure 1) .
Because of its clinical relevance in inflammation, a highly explored research topic is the functional interference between GR and NF-kB (see Table 1 ) (Barnes, 2001; De Bosscher et al., 2003b) . However, there is little consensus about the precise molecular mechanism(s) used by glucocorticoids (GCs) to inhibit NF-kB. In truth, GCs probably utilize different mechanisms to inhibit NF-kB, depending on the 'environment', for example, the particular target gene (that is, not all NF-kB-driven gene promoters have the same TFbinding site composition to drive gene expression), the cell type-dependent presence of certain cofactors, the surrounding histone code (i.e., the particular set of chromatin modifications), etc. (Natoli and De Santa, 2006; Vanden Berghe et al., 2006b) . Gene-repressing NRs should, therefore, be considered more as contextdependent, multitargeting effectors, rather than mediators of repression via a single pathway (De Bosscher et al., 2003a) .
To provide a glimpse of the possibilities for NR-TF cross-talk, we discuss herein the different proposed mechanisms for this cross-talk, particularly as exemplified by the prototypic GR and NF-kB cross-talk. Following the discussion of the detailed mechanistic aspects, we also highlight the physiological relevance and cross-talk mechanisms of other NRs that influence NF-kB activity. Proposed mechanisms can be divided generally into two categories: nuclear models and cytoplasmic models. However, as mentioned above, the dynamic nature of protein shuttling events make it likely that such strict boundaries do not exist in a real cell setting.
NF-jB and GR: mechanistic aspects

Nuclear models
Physical interaction between NF-kB and GR. Activated NRs block the activity of many other TFs, of which the most commonly studied are NF-kB and AP-1. The cross-talk is in many cases 'reciprocal', meaning that activated NF-kB can also interfere with the transactivation properties of NRs directly bound to DNA (Caldenhoven et al., 1995) . Therefore, it was most logical to assume that a direct physical interaction would form the basis of these mutual cross-talks, wherein the interacting TFs blocked each other's DNA-binding and/or transactivation functions. For GRa and NF-kB, a physical association in vivo was demonstrated in the A549 lung epithelial cell line (Adcock et al., 1997) . A series of deletion and point mutants of GRa pointed to an indispensable role for the DBD of GR for interaction with both the Rel homology domain and the C-terminal transactivation domains of RelA (Heck et al., 1994; Caldenhoven et al., 1995; Helmberg et al., 1995; Ray et al., 1995; Lide´n et al., 1997; Wissink et al., 1997; Moras and Gronemeyer, 1998) . Although the GR DBD was important for the interaction with RelA, DNA binding per se was not required, as point mutants in GR that specifically disrupted DNA binding were still capable of mediating transrepression of NF-kB (Heck et al., 1994; Caldenhoven et al., 1995; Helmberg et al., 1995) . Whether the first or second Zn finger in the DBD of GR is most important for transrepression of NF-kB is unresolved (Lide´n et al., 1997) , and may depend on the nature of the investigated responsive elements (promoter target gene and chromatin-or histone modificationdependent) in different cell lines (cofactor contextdependent) (see below). Similarly, the NF-kB-repressing capacity of the ER was also fully dependent on a complete ER DBD, as mutations within or overlapping with the DBD of ER abolished ER's ability to repress the NF-kB-dependent interleukin (IL)-6 promoter . Recently, with the aid of kinetic imaging studies (FRAP), the real-time DNA-binding kinetics of GR and NF-kB have been measured in vivo, revealing a quick turnover of DNA binding by both factors (Stavreva et al., 2004; Bosisio et al., 2006) . It is believed that this rapid turnover on DNA allows the cell to continuously sample changes in nucleoplasmic concentrations of GR and/or NF-kB in response to external stimuli. It would be exciting if one could determine whether mutual physical interactions of GR and NF-kB affect real-time binding kinetics of each factor specifically in transrepressing conditions.
Gene repression by activated NRs appears in most cases to be mediated through interaction with DNAbound transcription factors without the need for the NR to contact DNA by itself. A decade ago, it was believed that GRa could also mediate gene repression through contacting the DNA on so-called negative glucocorticoid response element (nGRE) elements. Subsequently, it was demonstrated, even for the 'prototypical' nGREcontaining genes, pro-opiomelanocortin and GnRH, that transcriptional repression by GR instead occurred through interference with the activity of NGFI-B/Nur77 and Oct-1 TFs, respectively (Phillips et al., 1997; Chandran and DeFranco, 1999) . Direct protein-protein interaction between NGFI-B and GR takes place primarily via their respective DBDs, although for GR DNA binding and homodimerization are not required. Thus, a mechanism quite similar to that proposed for transrepression between GR and AP-1 or NF-kB is at play (Martens et al., 2005) .
Interference with the BTM. For glucocorticoidinduced repression of the osteocalcin gene, direct binding of GR to DNA was found to occlude assembly of a functional basal transcriptional complex, as the GR-responsive DNA-binding element partially overlaps with the TATA box region . In a simplified cellular NF-kB activation system, circumventing the need for a cytoplasmic signaling cascade through the use of an exclusively nuclear fusion protein of the GAL4 DBD with RelA, which could constitutively drive expression from a GAL4-dependent luciferase construct, it was clear that GR-mediated repression was a nuclear event (De Bosscher et al., 1997) . The specificity of glucocorticoid repression was further found to depend on the TATA box context and thus to involve Bosscher et al., 2000b) . More evidence for an entirely nuclear glucocorticoid repression mechanism is supported by an unchanged in vivo footprinting pattern of NF-kB, bound to its response element in the GC-repressed ICAM promoter (Lide´n et al., 2000) . In addition, chromatin immunoprecipitation (ChIP) analysis of NF-kB RelA bound to the IL-8 promoter revealed that under conditions of gene repression, RelA remains bound to its response element (Nissen and Yamamoto, 2000) .
Comparison of a GC-repressed NF-kB-driven IL-8 promoter to an NF-kB-driven GC-unresponsive IkBa promoter revealed that recruitment of the polymerase II Ser2 C-terminal domain phosphorylating kinase pTEFb is a prerequisite for GC-mediated repression (Luecke and Yamamoto, 2005) . Whether this repression mechanism is exclusive for GR, or is also applicable to other NRs, is not clear yet. It also remains to be addressed how pTEFb/RNApol II regulation is affected at GR-unresponsive NF-kB-driven reporter constructs with a viral TATA box, or in cells of GC-resistant patients (De Bosscher et al., 2000b) . How GC can accomplish specific repression of the general transcription machinery is remarkable. However, new evidence demonstrates the existence of differentially phosphorylated RNA pol II forms with varying processivity and activity, depending on the C-terminal domain phosphorylation pattern (CTD code), which offers new opportunities for fine-tuning the basal transcription complex (Buratowski, 2003; Eissenberg and Shilatifard, 2006; Yamada et al., 2006) .
Cofactor-based models. As with ligand-dependent activation of NRs, transrepression by NRs also involves the recruitment of complexes of various cofactor molecules, a process that happens in a cell/tissue-and promoterspecific manner, although the precise molecular basis for this effect remains largely unknown. The early view that cofactors are exclusively nuclear and provide a static physical link between the TFs and the transcription machinery appeared too simplistic. Indeed, besides using their enzymatic activities (histone acetylation, methylation, etc.) to modify the chromatin and to regulate transcription, transcriptional cofactors are themselves subject to regulation by signal-mediated post-translational modifications, such as phosphorylation, acetylation, sumoylation, etc. (Xu et al., 2004; Wu et al., 2005b) . Counterintuitively, cofactors can even be detected in the cytoplasm, suggesting a broader functionality (Kao et al., 2001; Miska et al., 2001) .
As both NRs and NF-kB can interact with CBP/p300 (HAT-containing coactivators) to activate their target genes, it was proposed that competition between RelA and GR for limiting amounts of CBP/p300 could account for transrepression of NF-kB-dependent genes by GR (Sheppard et al., 1998) . In theory, this model immediately struggles with a lack of specificity, given that a large number of other TFs, which are not susceptible to GR-mediated gene repression, also utilize CBP/p300 for enhancing their transactivation properties (De Bosscher et al., 2000b , 2001 ). However, the question of how cofactors could only target a certain gene in a designated compartment in the nucleus while leaving the same factors associated with different genes in other compartments intact could be answered by adopting the concept of territorial subdivision (Francastel et al., 2000; Hager et al., 2000; Lemon and Tjian, 2000; Stenoien et al., 2000; Stewart and Crabtree, 2000) . Indeed, specific nuclear matrix-targeting signals have been found in different domains of GR (DeFranco and Guerrero, 2000) . Experimentally, however, it has been demonstrated that activation of GR does not affect the interaction between RelA and CBP and that a nuclear GAL4-RelA point mutant, defective in CBP recruitment, could still be functionally repressed by GR (De Bosscher et al., 2000b) , arguing against a general CBPcompetition model for inhibition or RelA by GR. Instead, CBP may act as an integrator, facilitating the physical interaction between GRa and NF-kB (McKay and Cidlowski, 2000) . Although GR interactions with specific coactivators are critical for direct GR target gene transactivation, they appear to be dispensable for at least certain aspects of GR-mediated transrepression of NF-kB (Wu et al., 2004) .
Histone acetylation plays a critical role in the regulation of inflammatory genes, and increasing evidence suggests that this activity is targeted by corticosteroids, while mediating their anti-inflammatory effects. The activated GR is able to recruit HDAC2 to activated inflammatory gene complexes, thus switching off NF-kB-driven gene expression (Ito et al., 2000) . Insights into the mechanisms of action of steroid hormones have also come from studies comparing agonists with antagonists. Because the GR antagonist RU486 does not recruit HDAC2 to the RelA/HATcontaining complex, it was concluded that GCs require HDAC2 recruitment for their full anti-inflammatory effect (Ito et al., 2001) . Along the same lines, an increase in inflammation and corticosteroid resistance, observed in chronic obstructive pulmonary disease and in asthmatic patients who smoke, is believed to be due to a reduction in HDAC2 activity and expression (Barnes, 2006) . The development of specific HDAC2-activating drugs may, therefore, represent a novel approach for the treatment of GC-resistant chronic inflammatory diseases.
Using the bioluminescence resonance energy transfer assay, Garside et al. (2004) found that RU486 efficiently recruited the corepressor NCoR to GR, unlike dexamethasone (a strong synthetic GR agonist), which recruited the coactivator SRC1. With respect to transrepression, RU486 was found to impair the interaction between GR and RelA, leading to the reduced recruitment of GR to the NF-kB-responsive region of the IL-8 promoter. Taken together, the mechanism whereby activated GR targets NF-kB-driven gene expression may involve recruitment of a fully functional corepressor complex that minimally contains HDAC2 and NcoR. NcoR and SMRT have been found to interact not only with NRs, but also with NF-kB, suggesting a more general role in mediating repression (Lee et al., 2000) . This hypothesis is further supported by the finding that, in NcoR-deficient macrophages, de-repression of NF-kB and AP-1-dependent gene networks involved in inflammation, cell migration and collagen catabolism can occur (Ogawa et al., 2004) . For SMRT, it was shown that de-repression involves IKKa-dependent phosphorylation, which stimulates a proteasome-dependent exchange of corepressor for coactivator complexes, serving as a prerequisite for NF-kB-mediated transcription and survival. It was further found that the SMRT-dependent de-repression coincides with p300-dependent acetylation of RelA itself (Hoberg et al., 2006) . The question thus remains whether NRs can block NF-kB-dependent transcription by deacetylase-mediated reversal of RelA acetylation and consequently promote recruitment of the initial (recycled) hormone receptor repressor complex or even a newly composed repressor complex, or alternatively, whether the NRs prevent the assembly of a transcription-competent activator complex.
Recently, it was also shown that the ability of certain NRs to inhibit inflammatory responses can be highly signal-specific. For example, the same gene, Cxcl10, that is activated by NF-kB following stimulation of Toll-like receptor-4 (TLR-4) with the pro-inflammatory compound LPS and is sensitive to GR-mediated repression, becomes resistant to GR-mediated repression when activated by the TLR-3 ligand polyinosinic-polycytidilic acid (poly I:C). The molecular basis for this selectivity involves signal-dependent usage of NF-kB RelA as an obligate TLR-4-specific coactivator of IRF3 transcription factor-driven Cxcl10 gene expression Reily et al., 2006) . Alternatively, the molecular basis determining responsivity to GC repression for the Cxcl9 gene as compared to the unresponsive IKBA (NFKBIA) gene involves the use of IRF3 as a specific coactivator of DNA-bound NF-kB Reily et al., 2006) . The role of IRF3 is not exclusive, however, as another factor, positive transcription elongation factor b (pTEFb), has been found to be a distinguishing cofactor determining responsivity to GCs for tumor necrosis factor (TNF)-mediated induction of gene expression of IL-8 as opposed to IkBa (Luecke and Yamamoto, 2005) , two NF-kB-controlled promoters whose NF-kB-binding sites differ by only one base pair. As a single nucleotide difference between two functional NF-kB-binding sites is sufficient to dictate alternative coactivator recruitment (Leung et al., 2004) , it is not surprising that different NF-kB-driven genes can display a different susceptibility to GR-mediated repression. Along the same lines, nuclear localization of a recently identified signaling component, SIMPL, is required for TNFa-dependent but not IL-1-dependent NF-kB activation, raising the question of whether and how NRs also target this TNFa-specific coactivator (Kwon et al., 2004) .
In conclusion, NRs cannot be regarded as general blocking agents of NF-kB-driven gene expression, because only a subset of NF-kB-driven genes is subject to NR-mediated gene repression. NRs can prevent the interaction of NF-kB with some required coactivators, but not others, providing the basis for signal-and promoter-specific transrepression. Considering the cellspecific repertoire of cofactors (qualitative and quantitative differences), the exact mechanism deployed by a given NR to mediate gene repression will inevitably also be highly cell context-specific. Moreover, as different NRs repress overlapping but also distinct sets of NF-kB target genes, another level of specificity is reached, opening up the way for combinatorial therapy strategies in combating inflammatory diseases . It remains puzzling how apparently identical liganded NRs are able to recruit either coactivator or corepressor complexes depending on a transactivation or transrepression context. In this respect, cofactor studies on liganded monomeric or dimeric GR conformations may be very informative. These results, taken together with the recently discovered signalspecific regulation of the cofactors themselves (Wu et al., 2005b) , suggest that it is unlikely that NRmediated transrepression could result from a simple competition mechanism between activated NF-kB and activated NRs for a limiting amount of the same coactivator(s). A plethora of arguments rather point to cofactor exchange models as a more likely explanation (Rosenfeld et al., 2006; Glass and Ogawa, 2006) .
Cytoplasmic models
Cytoplasmic sequestration of NF-kB. More than a decade ago, the discovery that glucocorticoids could induce upregulation of IkBa sparked the belief that GCs could effect gene repression by IkBa-dependent sequestration of NF-kB in the cytoplasm Scheinman et al., 1995) . Other NRs have also been shown to upregulate IkBa protein levels; these NRs include PR, AR, PPAR (reviewed in De Bosscher et al., 2003b) and retinoid-related orphan receptor alpha 1 (Delerive et al., 2001) . It remains puzzling, however, that no classical GRE has been found in the promoter for IkBa and that the GC-induced expression of IkBa is strictly cell type-dependent. Thus, upregulation of IkBa cannot be the sole mechanism through which NRs inhibit NF-kB-driven gene expression, particularly because transrepression also proceeds in the absence of novel protein synthesis and without removing NF-kB from its response elements in vivo (De Bosscher et al., 1997 , 2003b Lide´n et al., 2000; Nissen and Yamamoto, 2000) .
Contrasting with classical models, in cytosolic rat liver extracts, the NF-kB p50/RelA and IkBa complexes have been shown to interact with GR. Surprisingly, these interactions can occur even in the absence of glucocorticoids or of an inflammatory signal (Wide´n et al., 2003) (Figure 1) . Furthermore, the NF-kB-IkB complex had already been found to shuttle between the cytoplasm and the nucleus in the absence of signal (Johnson et al., 1999; Carlotti et al., 2000; Ghosh and Karin, 2002) . It was further found that cytoplasmic sequestration of RelA by IkBa leads to the relocalization of nuclear corepressors SMRT/NCoR to the cytoplasm. Both RelA and IkBa are able to directly bind SMRT, and RelA acetylation negatively modulates this interaction with SMRT (Espinosa et al., 2003) .
One piece of evidence that NRs can affect NF-kB shuttling was provided through the use of fluorescent fusion proteins. Activated GR was found to alter the timing of activated NF-kB RelA nuclear occurrence by increasing the nuclear export rate of RelA (Nelson, 1995) . However, a series of data argue that no exclusive relationship between NF-kB relocalization from the nucleus to cytoplasm, reduced NF-kB/DNA binding and elevation in expression levels of IkBa during GC repression appears to exist (De Bosscher et al., 2003b) .
Interference with other signal transduction pathways. Glucocorticoids have also been shown to interfere with cytoplasmic signaling pathways that impinge on the activation of NF-kB. In certain cell types, treatment with GCs leads to upregulation of mitogen-activated protein kinase phosphatase 1 (MKP-1), which dephosphorylates and thus prevents activation of ERK and p38 (Kassel et al., 2001; Lasa et al., 2002) and, as such, may inhibit downstream mitogen-actived protein kinase (MAPK)-dependent NF-kB transactivation (Vanden Berghe et al., 1998) . In line with this model, impaired MKP-1 activity exacerbates inflammation (Salojin et al., 2006) . As p38 MAPK is also implicated in the stabilization of pro-inflammatory gene mRNAs (e.g., of COX-2 (cyclooxygenase-2), TNFa, IL-6 and IL-8), MKP-1 induction by GCs consequently results in mRNA destabilization of the transcripts from these genes (Lasa et al., 2002) . However, the fact that in presence of cycloheximide, which blocks new protein synthesis (of MKP-1), GC-mediated gene repression of IL-6 still occurs proves that MKP-1 induction is not a universal transrepression mechanism (De Bosscher et al., 1997) . In addition, because neither TNFactivated ERK nor p38 activity is affected by GCs in L929sA fibroblasts, whereas GR efficiently represses IL-6 gene transcription in these cells, MKP-1 induction is unlikely to be a major determinant for explaining anti-inflammatory effects of GCs (De Bosscher et al., 2001) .
Another signaling pathway affecting NF-kB/GR cross-talk, in both directions, is the protein kinase A (PKA) pathway. PKA is able to phosphorylate RelA at Ser-276 within the Rel homology domain, allowing complex formation with the coactivator molecule CBP (Zhong et al., 1998) . Ser-276 phosphorylation was further found to be essential for RelA-mediated repression of GR-dependent transcription (the 'reciprocal' transrepression mechanism) (Doucas et al., 2000) . The catalytic subunit of PKA (PKAc) can associate with GR in vivo, and can potentiate GR-dependent transcription. Surprisingly, an exclusively cytoplasmic mutant of RelA (with a deletion of the nuclear localization signal) could still transrepress a GRactivated and GRE-driven mouse mammary tumor virus reporter gene. Similarly, a GRa mutant (D589-697) with predominantly cytoplasmic localization could also inhibit RelA-driven gene expression. Taken together with the above-mentioned observation, these results argue for a role for PKAc in mediating mutual cross-talk between GR and NF-kB in the cytoplasm (Doucas et al., 2000) . However, the presence of 'multiple' nuclear localization signals in GR together with the recent observation that both unliganded and liganded GRs continuously shuttle between the cytoplasm and nucleus (Savory et al., 1999) might indicate that the D589-697 GR mutant can still enter the nucleus, where it can mediate effects on NF-kB-driven gene activation. Moreover, substitution of RelA Ser-276 with Cys in the context of the exclusively nuclear GAL4-p65 fusion protein, capable of activating a GAL4-dependent reporter gene, demonstrated that transactivation by the RelA S276C mutant could still be efficiently repressed by activated GR, ruling out an exclusive dependence of PKA signaling for the transrepression mechanism (De Bosscher et al., 2000a) .
Although NF-kB and GR are widely recognized as mutually antagonistic regulators of adaptive immunity and inflammation, synergistic activities have been reported too, for example, when NF-kB-and GRresponsive elements were juxtaposed within a single promoter (Hofmann and Schmitz, 2002) . Along the same line, GC and NF-kB were found to cooperatively regulate gene expression of Toll-like receptor-2, a component of innate immunity, both in a direct manner and perhaps also indirectly, as GC-mediated negative cross-talk with p38 MAPK was also implicated in the synergistically enhanced TLR-2 expression (Shuto et al., 2002; Hermoso et al., 2004; Smoak and Cidlowski, 2004) .
Other signaling pathways also impact on NR functionality. For instance, the GR protein can be phosphorylated by the MAPK signaling pathway, and this phosphorylation inhibits GR-mediated transcriptional activation (Rogatsky et al., 1998) . How phosphorylation of GR might affect its subcellular localization, rate of nuclear import/export or turnover requires further investigation. As glucocorticoid-resistant asthma patients do benefit from a combination of MAPK inhibitor and GC therapy, this suggests a role for phosphorylation in GR functionality with respect to NF-kB transrepression mechanisms (Irusen et al., 2002) .
In the case of ER, allosteric control of the receptor was demonstrated by the ERK-activated p90 ribosomal S6 kinase 2 (RSK2), which phosphorylates Ser-167 on ER. Interestingly, antiestrogens can block RSK2-mediated activation of ER . Similarly, as the RSK2 kinase has also been linked to NF-kB signaling, inhibition of MAPK/RSK2 and GC therapy may reveal beneficial therapeutic effects (Panta et al., 2004) . Taken together, the observed differential results on MAPK signaling components, even with the same NR and depending on the cellular context, emphasize the diversity of regulatory possibilities of NRs when modulating the signaling pathways leading to activation of NF-kB.
Furthermore, because of the above-mentioned (see section: cofactor-based models) signal-specific and promoter-specific cofactor surroundings associated with either NR-or NF-kB-mediated gene activation, it is more likely that the reciprocal mechanisms of cross-talk Cross-talk between nuclear receptors and NF-jB K De Bosscher et al between NRs and NF-kB do not necessarily target the same cellular components.
Cross-talk between NF-jB and the ER
Estrogens play an important role not only in reproduction, but also in the skeletal, cardiovascular, immune and central nervous system (Jordan, 2002 (Jordan, , 2004 McDonnell and Norris, 2002; Pearce et al., 2003) . Their biological effects are produced through binding to two distinct receptors, ERa and ERb, which can activate or repress gene transcription (Nilsson et al., 2001) . The classical (genomic) mechanism of ER action involves estrogen binding to its cognate receptors, after which the receptors dimerize and bind to specific response elements, known as estrogen response elements (EREs) located in the promoters of target genes. Alternatively, ligand-bound ERs can regulate gene expression without directly binding to DNA through protein-protein interactions with other DNA-binding TFs in the nucleus. In addition, membrane-associated ERs mediate the non-genomic actions of estrogens, which can lead both to altered functions of proteins in the cytoplasm and to effects on the regulation of gene expression (Bjo¨rnstro¨m and Sjo¨berg, 2005; Gururaj et al., 2006; Manavathi and Kumar, 2006) . The functional interaction, or cross-talk, between ER and NF-kB has been suggested to play a key role in estrogen's ability to prevent age-related conditions and tumorigenesis in vivo (Dijsselbloem et al., 2004) . Pro-or anti-inflammatory roles of estrogens on NF-kB-dependent gene expression have been shown to strongly depend on cell type (signaling circuitries, cofactor dynamics, repertoire of ER isoforms and chromatin promoter context) (Cerillo et al., 1998; Maret et al., 1999; Wissink et al., 2001; Cheung et al., 2003; Cutolo et al., 2003; Bhat-Nakshatri et al., 2004; Kalaitzidis and Gilmore, 2005; Vanden Berghe et al., 2006a) or ligand metabolism (Cutolo et al., 2004) . Of special note, loss of ER function has been associated with constitutive NF-kB activity and hyperactive MAPK, because of constitutive secretion of cytokine and growth factors, which ultimately culminates in aggressive, metastatic, hormone-resistant cancers (Ali and Coombes, 2002; Pratt et al., 2003; Lu et al., 2004) .
One of the first reports describing a functional antagonism between ERa and NF-kB looked at regulation of the IL-6 cytokine gene . Because of the role of IL-6 in osteoclastogenesis (the formation of cells that function in the breakdown and resorption of bone tissue), an increased production of IL-6, as a consequence of the estrogen-depleted menopausal state, contributes to the increased resporption of bone which leads to osteoporosis . Recently, it has become clear that an overall increase in cytokine production, including TNFa, also increases the incidence of osteoporosis and other inflammatory conditions such as cardiovascular diseases and Alzheimer's disease (Pacifici, 1996; Ammann et al., 1997; Cacquevel et al., 2004) . From in vitro studies it was found that estrogens can block DNA binding of NF-kB to kB site promoters (Stein and Yang, 1995; Galien and Garcia, 1997; An et al., 1999) . However, a recent study by Cvoro et al. (2006) investigated the mechanism of ER-mediated repression of the endogenous TNFa gene, containing a composite AP-1/NF-kB element, by means of ChIP analysis and re-ChIP analysis. The latter technique allows identification of protein complexes that are simultaneously bound at the promoter in vivo. Not only did they find that estradiol treatment does not alter recruitment of c-Jun and NF-kB to the TNF-induced TNFa promoter, but they also discovered that the proinflammatory stimulus on its own leads to recruitment of unliganded ERa to the promoter at later time points, where ERa associates with NF-kB and c-Jun and functions as a coactivator. The addition of estradiol leads to loss of detection of ERa on the TNFa promoter, and the concomitant recruitment of one member of the p160 coactivator family member, GRIP, here functioning as a corepressor (Cvoro et al., 2006) . The notion that cofactors, previously identified either as solely coactivators or as corepressors, can switch functionality depending on the promoter context, probably by adopting different conformations, has been described before (Rogatsky et al., 2002) . Further studies are needed to address whether this mechanism can be generalized and extended to other cell types and other NF-kB target genes in vivo, or whether it is a peculiarity of the composite NF-kB/AP-1 element in the TNFa promoter. As a matter of fact, a series of earlier studies using EMSA analysis, in different cell types, points to the loss of NF-kB binding as the explanation for ERmediated transrepression, although again ER is likely to affect NF-kB by a variety of molecular mechanisms (reviewed in Kalaitzidis and Gilmore, 2005) . With regard to the specific role of cofactors in mediating cell-and ligand-specific ER responses (Jordan, 2002; Katzenellenbogen and Katzenellenbogen, 2002; Shang and Brown, 2002) , the development of pharmaceutical agents that target ER/cofactor interactions as therapeutics for estrogen-associated pathologies is currently a subject of intensive research (Heldring et al., 2004; Hall and McDonnell, 2005; Kong et al., 2005) .
Much effort has also focused on the development of novel SERMs (selective estrogen receptor modulators), because the transcriptional activation of proliferationpromoting ER target genes is mainly associated with breast cancer (Foster et al., 2001a, b; Wu et al., 2005c) , whereas transrepression of NF-kB activity by ER is mainly coupled to ER's beneficial anti-inflammatory effect and its protective role on bone metabolism. Tamoxifen is an anti-estrogen that is widely used in the clinic as an effective treatment for ER-positive breast cancer, but with clear drawbacks: besides the fact that certain tumors are resistant to tamoxifen, treatment with tamoxifen also has been associated with an increased incidence of endometrial tumors (Zhou et al., 2005a, b; Wu et al., 2005c) . cDNA microarray analysis indicates that estrogens and SERMs exert tissue-specific effects through ERa and ERb, resulting in unique profiles of induced target genes (Kian Tee et al., 2004) . The existence of ERa point mutants that favor NF-kB-based transrepression over DNA-bound ER target gene transactivation suggests that subtle changes in ER conformation can provoke distinct and differential biological outcomes. Because most results suggest that inhibition of the NF-kB pathway is a valid strategy to combat breast cancer in many individuals, continued research now focuses on the development of SERMs that are not only anti-proliferative but also antiinflammatory and possibly pro-apoptotic. Many currently used SERMS do not have the capacity to efficiently block NF-kB (Biswas et al., 2005) ; however, raloxifene has recently been shown to remove RelA from DNA in an ERa-dependent manner in multiple myeloma cells (Olivier et al., 2006) . In addition, the recently developed non-steroidal compound WAY-169916 can selectively block NF-kB signaling through binding to either ERa or ERb, but fails to induce classical ER-mediated target gene effects, suggesting that such compounds could be valuable for the treatment of ER-positive breast cancers where inhibition of NF-kB can induce apoptosis (Chadwick et al., 2005) .
Estrogen and NF-kB activation can both increase cell proliferation by inducing expression of the cell cycle regulatory protein Cyclin D1; moreover, NF-kB can enhance cell survival by inducing the expression of several anti-apoptotic genes (see Dutta et al., 2006) . The advantage of NF-kB-selective ER modulators may lie in their ability to block the proliferative and pro-survival effects of enhanced NF-kB signaling, which currently is an inevitable side effect and a possible cancer-promoting event, when estrogen signaling is completely inhibited by current ER-positive breast cancer treatments with aromatase inhibitors (which block estrogen synthesis) (Biswas et al., 2005) . The importance of ER-mediated inhibition of NF-kB in breast cancer is further supported by the observation that active DNA-bound NF-kB is detected in the majority of ER-negative breast tumors, whereas active NF-kB is absent in their ERpositive counterparts (Biswas et al., 2004) . Thus, NF-kB inhibitors may be valuable for the treatment of ERnegative breast cancer and, perhaps even in the treatment of hormone-resistant ER-positive breast cancers.
In contrast to the negative cross-talk between ER and NF-kB, positive synergism between these transcription factors has also been reported. In particular, synergistic activation by ER and NF-kB has been shown for the gene encoding the serotonin 5HT1A receptor (Wissink et al., 2001) . The molecular basis for this synergy needs to be further explored, and this positive interaction between ER and NF-kB may be rare and highly promoter-specific. In another experimental setting, related to gender-specific regulation of longevity genes, an estradiol-mediated increase in MAPK activation was found to activate the NF-kB signaling pathway, thus driving the expression of antioxidant enzymes such as Mn-superoxide dismutase and glutathione peroxidase; this mechanism provides an elegant explanation for the antioxidant properties of estrogen and its effects on longevity-related genes Vina et al., 2005) .
Interestingly, non-genomic mechanisms of cross-talk between ER and NF-kB have also been described with important biological implications for human health. Indeed, through a non-genomic effect of ER, the activation of the NF-kB-dependent gene product COX-2 leads to production of the atheroprotective prostacyclin, PGI2 (Egan et al., 2004) , suggesting an explanation for why chronic use of selective COX-2 inhibitors (used in cases of chronic inflammatory diseases) may potentially undermine the cardiovascular protective effects of estrogen.
Cross-talk between NF-jB and the progesterone receptor Activation of the progesterone receptor can lead to inhibition of NF-kB-driven gene expression (Kalkhoven et al., 1996) . This cross-talk has a biological significance in keeping the uterus quiescent before the onset of labor and parturition. At term, fetal lung surfactant protein secretion activates fetal amniotic fluid macrophages, which in turn activate NF-kB in the uterine wall (Condon et al., 2003; Mendelson and Condon, 2005) . Activated NF-kB leads to the expression of proteins that are believed to facilitate uterine contractility, such as COX-2, but NF-kB also antagonizes PR-activated target genes that modulate uterine contractility by directly interacting with PR, reducing its DNA binding and transcriptional activity (called 'reciprocal' repression). Recently, it was found that an NF-kB-induced change in the expression of a uterine PR isoform also forms the basis of a decrease in PR DNA-binding capacity in the laboring myometrium (Condon et al., 2006) .
Cross-talk between NF-jB and the AR
Reciprocal negative cross-talk has also been observed between NF-kB and the AR. Palvimo et al. (1996) found that activated AR does not cause increased levels of IkBa, which could sequester and inactivate RelA. Instead, they found that a physical association, albeit weak, between AR and RelA could explain their mutual repression. In a later study, transcriptional interference between AR and AP-1 or NF-kB was suggested to be mediated, at least in part, through competition for intracellular CBP (Aarnisalo et al., 1998) . However, similar to the reservations for the role of coactivator squelching in GR-NF-kB cross-talk (described above), it seems unlikely that coactivator competition between AR and NF-kB would provide sufficient biological specificity. At the prostate-specific antigen (PSA) promoter, it was found that cross-modulation between AR and RelA may occur by a novel mechanism involving binding to a common cis-DNA element (Cinar et al., 2005) .
Androgens have been reported to inhibit IL-6 production by bone marrow-derived stromal cells (Bellido et al., 1995) . Suppression of osteoblast IL-6 production by androgens may cause, at least in part, the anti-resorptive effects of androgens on bone (Hofbauer and Khosla, 1999) . NF-kB has been implicated in the repression of the AR gene promoter (Supakar et al., 1995; Nakajima et al., 1996) . Paradoxically, in Sertoli cells, NF-kB elements in the AR promoter have been identified as being responsible for increased AR expression, representing an important (cell type-specific) regulatory mechanism required to maintain efficient spermatogenesis (Delfino et al., 2003) . Much like the reciprocal cross-talk between ER and NF-kB in breast cancer, NF-kB activation blocks the proliferation of androgen-dependent prostate cancer cells, whereas the proliferation of cancer cells devoid of AR is not affected by NF-kB activation (Nakajima et al., 1996) . Conversely, constitutive NF-kB activation has been demonstrated in AR-negative prostate cancer cell lines (Suh et al., 2002) . As relatively few NF-kB target genes have been identified in cDNA expression microarray analyses of prostate cancer cells, further studies will be required to determine whether NF-kB plays a role in human prostate cancer development and/or progression, and to characterize the potential of NF-kB as a therapeutic target in prostate cancer (Suh and Rabson, 2004) . Finally, with respect to ageing processes, an increase in NF-kB activity in the liver is believed to be related to the androgen desensitization that occurs during liver cell senescence (Supakar et al., 1995) .
Cross-talk between NF-jB and PPAR/liver X receptor PPARs (including subtypes PPARa, b and g) and LXR (Liver X receptor) are heterodimeric NRs that form a complex with RXR and belong to the class of adopted orphan receptors. Although the endogenous ligands that activate these receptors in vivo are poorly characterized, all PPAR members can be activated by various fatty acids (Forman et al., 1996; Kliewer and Willson, 1998) . Besides their role as transcriptional regulators of fatty acid metabolism, PPARs also function as regulators of inflammatory responses. Thus, PPAR agonists could potentially be used as a second line of defense and protection in combinatorial treatment with glucocorticoids as such agonists have shown therapeutic effectiveness in chronic inflammatory disease models, such as atherosclerosis or obesity-induced insulin-resistance . Notably, some PPAR ligands have been shown to reduce NF-kB activity in a receptorindependent manner, for example, the PPARg-agonist 15dPGJ2 can directly inhibit IKK and the DNAbinding activity of NF-kB (Rossi et al., 2000; Straus et al., 2000) .
PPARa ligands, but not PPARg ligands, inhibit IL-1-induced production of IL-6, prostaglandin and COX-2 in human aortic smooth-muscle cells, which play an important role in plaque formation and post-angioplasty re-stenosis. In the vascular wall, PPARa inhibits the inflammatory response of aortic smooth-muscle cells and decreases the concentration of plasma acutephase proteins, having a positive outcome on the process of atherosclerosis and re-stenosis (Staels et al., 1998; Delerive et al., 1999) . PPARa also prevents macrophage foam cell formation in the peritoneal cavity .
PPARa-mediated repression of NF-kB signaling involves a direct protein-protein interaction between PPARa and RelA (Delerive et al., 1999) . In addition, activated PPARa can cause a small upregulation of IkBa protein levels. The transcriptional cooperation between ligand-activated PPARa and NF-kB in upregulating IkBa involves recruitment of DRIP/TRAP complexes onto the Sp1 site flanking the kB site in the IkBa promoter (Delerive et al., 2002) . Whether this mechanism can be generalized for other NRs is not known. Nevertheless, as discussed above for GR, the functional contribution of IkBa upregulation to NRmediated NF-kB transrepression is believed to be marginal.
Besides PPARa, PPARg has also been shown to have anti-inflammatory and NF-kB-inhibitory effects in other experimental settings or target cells. For instance, activation of PPARg in macrophages and foam cells inhibits the expression of activated pro-inflammatory NF-kB target genes such as inducible nitric oxide synthase (iNOS), matrix metalloproteinase-9 (MMP9) and scavenger receptor A. PPARg may also affect the recruitment of monocytes to atherosclerotic lesions (Neve et al., 2000) and can suppress inflammation in intestinal epithelial cells (Eun et al., 2006) . A novel anti-inflammatory mechanism in the gut involves PPARg-dependent increased nuclear export of transcriptionally active NF-kB (Kelly et al., 2004) . Taken together, it is clear that the PPAR class of NRs can also be defined as potential targets for the treatment of chronic inflammatory diseases, including atherosclerosis, inflammatory bowel disease and rheumatoid arthritis, based on the ability of PPARs to inhibit NF-kB activity.
Novel mechanisms of action of clinically used drugs are also being discovered. Statins, which are competitive inhibitors of 3-hydroxy-3-methylglutarylcoenzyme A reductase and are used as cholesterollowering agents, have additional anti-inflammatory effects on NF-kB-driven genes by restoring PPARa transrepression activity upon inhibition of PKCa (Paumelle et al., 2006) . In this respect, statins are beneficial for patients suffering from the metabolic syndrome, which encompasses inflammatory, diabetic, and cardiovascular disease states (Sowers, 2003; Haffner et al., 2006) . LXRs, activated by oxysterols (oxygenated cholesterol derivatives) function not only as sensors of cellular cholesterol homeostasis, but also play a role in adaptive immune responses and have been characterized as regulators of the macrophage inflammatory pathways. LXR agonists tone down the inflammatory response to bacterial pathogens by inhibiting the production of a range of NF-kB-dependent cytokines, including IL-1b, IL-6, iNOS, MMP9, COX-2. In contrast, LXR knockout mice display an exaggerated response to LPS, which is a potent activator of NF-kB. The precise molecular mechanism of LXR-mediated inflammatory gene repression is not yet known, but clearly involves inhibition Cross-talk between nuclear receptors and NF-jB K De Bosscher et al of NF-kB . Apparently, different NR family members recruit different cofactors to cross-talk with NF-kB. For example, the repression of inflammatory genes by PPARg agonists requires NcoR, whereas estrogen-dependent inhibition of NF-kB requires GRIP, a cofactor originally identified as a coactivator for GRE-driven gene expression. These surprising differences in NR-dependent cofactor functionalities again demonstrate that specific NR-mediated repression of NF-kB-driven genes occurs by distinct mechanisms Cvoro et al., 2006) .
Separating NR functionalities?
Three important findings favor the existence of a molecular basis for the separation of the beneficial effects of corticosteroids or other steroids (i.e., transrepression or inhibition of NF-kB and AP-1-driven cytokine gene expression) from their 'detrimental' side effects (i.e., transactivation or activation of steroidresponsive genes regulating metabolic processes). First, the identification and characterization of in vitro selective agonists/antagonists of NRs suggest that only a subset of the NR functions, induced by the natural ligand, can selectively be elicited (Resche-Rigon and Gronemeyer, 1998; Vanden Berghe et al., 1999b) . Second, studies with knock-in mice that express mutant GR receptors defective in their dimerization functions and therefore incapable of binding DNA indicate that the NF-kB transrepression pathway is still functional. From these experiments, it can be concluded that the anti-inflammatory action of glucocorticoids mainly arises from the 'negative' cross-talk of GR with NF-kB/AP-1 and can be separated from GR's DNA binding-dependent transactivation pathway (Reichardt et al., 1998 (Reichardt et al., , 2000 (Reichardt et al., , 2001 . Third, the finding that the interactions of GR with specific coactivators appear to be dispensable, to some extent, for GR-mediated transrepression of NF-kB supports a model wherein GR-mediated repression is not intrinsically linked to activation and can be separated mechanistically (Wu et al., 2004) . Figure 2 illustrates the two main pathways that GR uses to modulate gene expression and the rationale behind the strategy of attempting to develop molecules that can separate NR functionalities.
Selective NR modulators
Since the discovery of cortisone, much effort has been devoted to modifying the steroid backbone to achieve an improved therapeutic index. However, the overall results with respect to side effect profiles have been rather disappointing (Markham and Bryson, 1995) . The field was re-energized when pharmacologists and chemists realized the need to separate GR-mediated transcriptional activation from transcriptional repression. Still, reduction of GR transactivation properties by promising 'dissociating' ligands seemed to be highly cell Figure 2 The molecular rationale behind the separation of GR functionalities. In the absence of ligand, GR is predominantly cytoplasmic and is associated with heat shock and chaperone proteins. Binding of glucocorticoid (black filled circle) or the nonsteroidal GR modulator Compound A (CpdA, yellow filled circle) induces the nuclear translocation of GR. Glucocorticoid-activated DNA-bound dimeric GR leads to the expression of metabolic gene products (indicated by the plus sign), which contribute to the occurrence of side effects associated with long-term glucocorticoid usage. A minor pathway leads to the expression of antiinflammatory proteins, including lipocortin-1, secretory leukoprotease inhibitor, CC protein 10, IL1-receptor antagonist and in some cases IkBa. The anti-inflammatory effects of glucocorticoids are mainly mediated through interference of GR (presumably via GR in its monomeric form) with the transactivation potential of NF-kB, blocking NF-kB-driven gene expression (indicated by the minus sign). CpdA-activated GR does not induce GRE-driven gene expression and only causes transrepression of NF-kB-driven genes. This dissociated property of CpdA makes it not only an interesting fundamental research tool to explore distinct GR-mediated biological effects but also opens avenues for anti-inflammatory applications in the clinic, because a better side effect profile is expected.
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Attention now focuses on the development of nonsteroidal steroid receptor modulators. One recent example is CpdA (Compound A), a plant-derived nonsteroidal compound that interacts with GR and elicits the desired dissociated properties: CpdA potently inhibits NF-kB-driven gene expression in a GR-dependent manner, but fails to activate GRE-dependent gene expression, consequently lacking unwanted diabetogenic effects in vivo (De Bosscher et al., 2005) . It needs to be further investigated whether this type of compound affects other GR target genes involved in osteoporosis, muscle wasting and psychosis/neurosis. Nevertheless, such dissociating ligands may become successful lead compounds for drug development. Conceivably, the molecular rationale for the dissociated effect probably resides in a differential cofactor requirement that may be dictated by the different conformations, which different ligands can impose upon the GR.
Today, various examples of structurally unrelated GR modulators exist, which seem to support this differential cofactor usage hypothesis. First, ursodeoxycholic acid (UDCA), which is defined as a bile acid despite carrying a steroidal structure and is used as an immunomodulatory agent in the treatment of various liver diseases, is capable of functionally modulating GR (although its specificity of binding to GR is a debated issue) and of suppressing NF-kB-driven gene expression (Miura et al., 2001; Bellentani, 2005) . UDCA attenuates the interaction between GR and the p160 family protein TIF2/ GRIP1, indicating that UDCA-stimulated GR cannot activate AF-2, a mechanism reminiscent of RU486 antagonist-bound GR (Roux et al., 1999; Miura et al., 2001; Schulz et al., 2002) . Second, AL-438, derived by modifying a synthetic progestin scaffold, was found to be completely competent for transcriptional repression of NF-kB-driven genes, but only a partial agonist for GR-mediate transcriptional activation, and thus capable of separating at least some GR activities in a genespecific manner. The mechanism of action of AL-438 involves differential coactivator recruitments of GRIP1/ TIF2 versus PGC-1; the latter seems preferentially used in steroid-mediated glucose upregulation (Coghlan et al., 2003) . Third, a series of related arylpyrazole compounds can elicit different expression patterns on 17 endogenous GR target genes in different cell types (i.e., lung, preadipocyte and preosteoblast), demonstrating that subtle differences in ligand structure can have profound effects on transcriptional regulatory activities of NRs (Wang et al., 2006) .
Structurally different steroidal ER ligands can also induce dramatically different gene expression profiles in a single cell type (Shang and Brown, 2002; Jordan, 2004; Kian Tee et al., 2004) , further supporting the idea that even with the same set of cofactors present in the cell, a different biological outcome can still be produced, depending on the inducing ligand. In order to predict and achieve a specific biological outcome with new NR ligands, an important goal will now be to determine, by crystallization studies (Necela and Cidlowski, 2003) , how changes in the topology of the ligand-binding pocket induced by these novel ligand structures affect the specific NR's activity spectrum.
Novel prospects and research areas
It is now clear that in order to unravel cross-talk mechanisms between NF-kB and NRs, we cannot limit ourselves to the study of only these two proteins. Instead, we need to look beyond the first level of simple interaction and to expand our research area to other layers of regulatory mechanisms, imposed by chromatin-embedded histone or transcription-and/or cofactormodifying proteins. Undoubtedly, the dissection of molecular pathways used by SnuRM (Selective Nuclear Receptor Modulators) will be of paramount importance to allow the design of increasingly selective ligands, which can regulate the activity of a receptor in a unique tissue-and/or cell-specific manner (e.g., only where the inflammation takes place). Future developments for the clinic could include the use of peptide aptamers (protein recognition agents that block protein-protein interactions), which could interfere with NR activity in a specific manner by mimicking NR/cofactor interactions (Gronemeyer et al., 2004) .
Post-translational modifications of transcription factors and/or cofactors Apart from well-known 'classical' (de)phosphorylation processes that can switch on/off or modulate the activity of many proteins, it has become clear that TF activity itself can also be fine-tuned by a variety of other posttranslational protein modifications, such as acetylation, methylation and sumoylation (see also Perkins, 2006) . For example, acetylation of ERa by the p300 acetylase in a ligand-and SRC-dependent manner modulates the gene-regulatory activity of this NR (Kim et al., 2006) . Recently, it was also found that glucocorticoid binding induces acetylation of the GR protein itself and that subsequent HDAC2-mediated deacetylation of GR is necessary to enable its NF-kB-inhibitory activity (Ito et al., 2006) .
It will be interesting to further investigate how liganddependent NR activation leads to a specific pattern of factor modifications linked to transactivation versus transrepression. In a recent study, ligand-dependent sumoylation of the PPARg LBD was found to recruit NCoR/HDAC3 complexes to inflammatory gene promoters and to prevent corepressor clearance of the promoter by proteasome components, which maintain the promoter in a transrepressed state. Of special note, sumoylation rather than ligand binding is the critical event that determines whether PPARg attracts coactivator or corepressor complexes .
Recently, not only NRs but also their coregulators have been shown to be targets of post-translational modifications (e.g., phosphorylation, acetylation, methylation, etc.), upon activation of diverse cellular signaling pathways (Rosenfeld et al., 2006; Baek and Rosenfeld, 2004 ). It will be a challenge to unravel the combinatorial TF/cofactor code required to achieve specific gene responses (Xu et al., 2003; Wu et al., 2005b) .
Histone methylation, chromatin remodeling and DNA methylation Histone methylation has long been considered to be exclusively linked to gene repression. However, a recent study investigating histone modifications involved in thyroid hormone receptor (TR)-mediated transcriptional regulation revealed that repression by unliganded TR is associated with a substantial increase in methylation of histone H3 Lys-9 (H3-K9), but a decrease in methylation of H3 Lys-4 (H3-K4) and of H3 Arg-17 (H3-R17). Upon transcriptional activation by liganded TR, a substantial decrease in both H3-K4 and H3-K9 methylation and a robust increase in H3-R17 methylation were observed (Li et al., 2002) . The methyltransferase CARM1 (coactivator-associated arginine methyltransferase 1) has been found to enhance transcriptional activation by liganded NRs through interaction with the coactivators p160 and CBP and through methylation of histone H3 at Arg-17 (H3-R17). CARM1 has recently also been linked to NF-kBmediated transcription through H3-R17 methylation. In addition, CARM1 physically interacts with NF-kB and is recruited to NF-kB-regulated genes (Miao et al., 2006) . In contrast, the histone demethylase lysinespecific histone demethylase 1 (LSD1) has been found to promote AR-dependent transcription. Whether the variety of (de)methylases (CARM1, PRMT2, G9A, LSD1, Ezh2) are preferred targets involved in hormone-dependent NF-kB transrepression, has not yet been fully addressed (Varambally et al., 2002; Xu et al., 2003 Xu et al., , 2004 Metzger et al., 2005; Lee et al., 2006) . Today, histone methylation biology has reached additional complexity, since the discovery of mono-, di-or trimethylbranches on lysine residus and the identification of various (de)methylating enzymes, suggesting that the original histone methylation -repression paradigm is too simplistic (Dutnall, 2003; Peters et al., 2003; Schotta et al., 2004; Lee et al., 2006; Shilatifard, 2006) .
Recent evidence has shown that RelA-mediated repression of an integrated GRE-driven MMTV promoter construct requires the brahma-related gene 1 (Brg1) chromatin-remodeling activity (Burkhart et al., 2005; Chen et al., 2006) . Reciprocally, differential NF-kB target gene expression was recently found to rely on different (antagonistic) functions of the chromatinremodeling complexes Brg1, Brm, Mi-2b (nucleosome remodeling and histone deacetylase (NuRD)) (RamirezCarrozzi et al., 2006; Vanden Berghe et al., 2006b) . Of special interest, expression of the Mi-2/NuRD complex component metastasis associated protein (MTA) is hormonally regulated and suggests that the stoechiometry of chromatin-remodeling complexes is under hormone control too (Fujita et al., 2003 Bowen et al., 2004) . Furthermore, interesting associations have been reported of hormone receptors with a nucleosomal methylation complex, which includes Brg1 as well as CARM1, but its potential involvement in NF-kB transrepression remains to be proven (Xu et al., 2004) . Finally, cell-and hormone-specific responses were also found to depend on the promoter DNA methylation status. As an example, glucocorticoids were found to regulate DNA demethylation within a key enhancer of the rat liver-specific tyrosine aminotransferase (Tat) gene. As a stronger subsequent glucocorticoid response is observed, demethylation appears to provide memory of the first stimulation. During development, this demethylation occurs before birth, at a stage when the Tat gene is not yet inducible, and it could thus prepare the enhancer for subsequent stimulation by hypoglycemia at birth. In this respect, demethylation appears to contribute to the fine-tuning of the enhancer and to the molecular memory of a regulatory event during development (Thomassin et al., 2001) . In another context, it was shown that the partial estrogenic activity of tamoxifen in the uterus, which increases the incidence of endometrial cancer, is dependent on hypomethylation of the PAX2 gene (Wu et al., 2005a) . Finally, the GR promoter has also been shown to be susceptible to regulation by DNA methylation. Specifically, it is reported that certain maternal behaviors (increased pup licking and grooming and arched-back nursing) by rat mothers can alter the offspring's epigenome, including the DNA methylation status of the GR gene promoter in the hippocampus (Weaver et al., 2004; Meaney and Szyf, 2005; Szyf et al., 2005) . However, further study is required to determine whether NF-kB transrepession by hormones is also susceptible to dynamic regulation by DNA methylation (Kirillov et al., 1996; Bird, 2003; Murayama et al., 2006; Vanden Berghe et al., 2006b ).
Post-transcriptional effects
Up to this point, this review has described only transcriptional effects of cross-talk between NR and NF-kB. However, activated GR can also affect NF-kBdependent gene expression by post-transcriptional mechanisms. A classical post-transcriptional effect of GR is destabilization of mRNA from NF-kB-driven genes (i.e., iNOS, TNFa, GM-CSF, COX-2) (Tobler et al., 1992; Delany et al., 1995; Chaudhary and Avioli, 1996; Lasa et al., 2001) . Recently, a novel mechanism of posttranscriptional regulation by NR cofactors has been unveiled. Because of their structural relationship to proteins involved in splicing, further exploration demonstrated that some of the NR transcriptional coregulators are also part of the spliceosome. Thus, a subset of NR coregulators acts as dual-function 'coupling' proteins between transcription and splicing, providing the molecular basis for a quality control checkpoint. Hormonal stimuli thus control not only the quantity but also the 'nature' (exon content) of their target gene products (Auboeuf et al., 2005) . In 1999, O'Malley and co-workers described the isolation and functional characterization of SRA, a bona fide transcriptional coactivator selective for the AF1 transactivation domain of steroid receptors and present in a steady-state coregulator complex with the AF2 coactivator SRC-1, but very much differing from other known protein coregulators, as SRA is an RNA transcript (Lanz et al., 1999 (Lanz et al., , 2002 (Lanz et al., , 2003 . Similarly, there has been a wave of newly discovered mRNA expression regulators, termed microRNAs, which act at multiple levels as regulators of gene expression in eukaryotes, and which are processed from larger transcripts by sequential action of nuclear and cytoplasmic ribonuclease III-like endonucleases (Lund et al., 2004) . Consequently, it is likely that more of these RNA regulators of mRNA expression will undoubtedly soon emerge in the field of NF-kB and NR research.
Concluding remarks
Today, various studies focusing on the benefits, side effects and risks of hormone therapies have generated debate and confusion among clinicians, researchers, and the lay public. Herein, we have reviewed how NR modulators elicit complex tissue-and gene-specific responses and what their impact is on NF-kB-driven gene expression. Major advances in our knowledge of molecular steroid hormone endocrinology have significantly affected modern hormone therapy protocols and pharmaceutical development. Seventy years after the discovery of 'Compound E' (i.e., the well-known steroidal compound cortisone), 'Compound A' (CpdA), a plant-derived non-steroidal GR-modulator that specifically inhibits NF-kB in the absence of 'metabolic' GRE-driven side effects, may start a new chapter in GC pharmacology, which is directed at improved medical anti-inflammatory applications. Because of recent technological advances that aid in making traditional natural product-based libraries more compatible with high-throughput screening, there is a renewed interest in the chemical diversity of natural products in the field of NR drug discovery (Koehn and Carter, 2005) . The outcome of this research may reveal novel unexpected concepts in hormone pharmacology. More research will reveal whether CpdA and variants thereof or other NR-modulating (natural) compounds will emerge as effective anti-inflammatory drugs and whether they will succeed in knocking cortisone from its pedestal.
A fertile area for future therapeutic exploration involves the use of combinations of several compounds that act on different NR pathways (e.g., selective GR modulators and selective PPAR modulators). This strategy may prove successful in achieving specific receptor regulation and a decreased side effect profile. For chronic inflammatory disorders, patientspecific tailor-made symptomatic relief may evolve to either multifocal therapeutics or to alternating therapeutics, which might prevent the occurrence of therapy resistance.
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